AxoGen (NASDAQ:AXGN) is a medical technology company headquartered in Alachua, Florida, that specializes in developing and commercializing innovative solutions for peripheral nerve repair and regeneration. Since its inception and subsequent public listing on the NASDAQ in 2013 under the ticker AXGN, the company has focused on providing surgeons with off-the-shelf, biologically based products that support the body’s natural healing processes following nerve injury or surgical intervention.
The company’s core product portfolio includes the Avance® Nerve Graft, a processed human nerve allograft that serves as an alternative to traditional nerve autograft procedures. Accompanying this offering are the Axoguard® Nerve Connector and Axoguard® Nerve Protector—porcine-derived extracellular matrix devices designed to guide and protect regenerating nerve tissue. More recently, AxoGen introduced the Avive® Soft Tissue Membrane, a human-derived biomaterial engineered to reduce scar tissue formation and improve outcomes in soft tissue repair procedures.
AxoGen’s products are utilized by surgeons across a range of specialties including plastic and reconstructive surgery, orthopedics, sports medicine, and neurosurgery. The company maintains direct sales operations in the United States and Canada and collaborates with distribution partners in Europe, Asia Pacific and Latin America to extend its global footprint. In addition to expanding its geographic reach, AxoGen invests in clinical education and training programs to support physician adoption and to generate real-world evidence of product performance.
Under the leadership of President and Chief Executive Officer David L. Hart, AxoGen continues to advance its research and development pipeline while strengthening its commercial infrastructure. The management team’s strategic priorities include broadening the application of existing products, pursuing regulatory approvals in new markets, and exploring collaborations to enhance its technology offerings. Through these efforts, AxoGen aims to address the growing clinical need for effective nerve repair solutions and to improve functional outcomes for patients worldwide.
